| 영문 | fulminant hepatitis | 한글 | 전격간염 |
|---|---|---|---|
| 설명 | 바이러스 간염의 한 형으로 급성 황색위축증이라고도 부른다. 간세포의 대부분이 괴사상태로 되며 환자는 보통 사망한다. 황달이 나타나기 전부터 이미 증상은 현저히 진행하여 황달의 출현도 빠르고, 급성 발열을 수반하며 점막이나 피하출혈을 볼 수 있다. 간의 압통을 수반하는 수도 있다. 위축에 의하여 간은 자주 작아진다. 최후에는 의식장애를 초래하여 졸음이 오고 혼미상태로 되며 간성혼수로 진행하여 사망하게 된다. 증상이 시작되어 2~3주 내에 간뇌병증까지 진행하는 간기능 상실을 전격성 간기능상실이라고 부르며, 진행 속도가 빠르지 않아서 3개월에 이르러 간기능상실에 빠지는 것은 아급성 간기능상실이라고 부른다. 모든 간염 바이러스가 모두 일으키지는 않는다. 간염A바이러스와 간염E바이러스는 보유자 상태나 만성 간염을 거의 일으키지 않는다. 기타 다른 감염 또는 비감염성 원인, 특히 약물과 독소도 본질적으로 동일한 증후를 일으킬 수 있다. 그러므로 바이러스성 간염의 진단과 각 간염 바이러스를 구별하는데는 혈청학적 검사가 필수적이다. |
||
| CCH | C-cell hyperplasia; chronic chloride hemagglutination; chronic cholestatic hepatitis |
|---|---|
| CH | case history; Chediak-Higashi [syndrome]; chiasma; Chinese hamster; chloral hydrate; cholesterol; Ch... |
| HA | H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli... |
| HBV | hepatitis B vaccine; hepatitis B virus |
| HDV | hepatitis D virus; hepatitis delta virus |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
|---|---|
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| giant cell hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| viral hepatitis | Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver. (12 Dec 1998) |
| viral hepatitis type A | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
| viral hepatitis type B | A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients. Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis. (05 Mar 2000) |
| viral hepatitis type C | Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family. Synonym: hepatitis C, virus C hepatitis. (05 Mar 2000) |
| viral hepatitis type D | Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis. Synonym: delta hepatitis, hepatitis D. (05 Mar 2000) |
| viral hepatitis type E | Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa. Synonym: hepatitis E. (05 Mar 2000) |
| viral hepatitis vaccines | Any vaccine raised against any virus or viral derivative that causes hepatitis. (12 Dec 1998) |
| virus A hepatitis | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
| virus B hepatitis | A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients. Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis. (05 Mar 2000) |
| virus C hepatitis | Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family. Synonym: hepatitis C, virus C hepatitis. (05 Mar 2000) |